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Carnitine palmitoyl-transferase hasbeen extracted with 0.5% Tween-20 from human liver homogenate and purified to homogeneity. The purified 
enzyme has a native Mr of 274 kDa. The subunit Mr is of 66 kDa, as shown by SDS-PAGE and immunoblots obtained with antibodies raised 
against human CPT. Purified CPT shows high affinity for palmitoyl-CoA and palmitoyl-carnitine and is not inhibited by malonyl-CoA. Seven 
tryptic peptides and the N-terminal of purified human CPT have been sequenced, and found homologous to rat CPT sequence. Both antibodies 
and peptide sequences are important tools for the investigation of the molecular basis of CPT deficiency in man. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Carnitine palmitoyl-transferase (CPT) (EC 2.3.2.21) 
allows long chain acyl-CoAs to cross the mitochondrial 
membranes by catalyzing their reversible conjugation 
with L-carnitine [1]. One part of CPT activity is 
associated with the outer mitochondrial membrane 
while another pool of CPT activity is in close relation- 
ship with the inner mitochondrial membrane [2]. It is 
still controversial whether the two pools express the 
activity of a single protein, differently located in 
mitochondrial membranes, or of two different en- 
zymes. 
CPT has a key-function in the regulation of fatty 
acids oxidation. Accordingly, its activity is finely 
regulated by malonyl-CoA inhibition and by hormonal 
action, mostly of glucagon and insulin [3]. 
Inherited eficiency of CPT causes muscle weakness, 
cramps and myoglobinuria n adults [4] and coma, non- 
ketotic hypoglycemia, elevation of transaminases and 
free fatty acids in infants [5]. 
As a first step towards the understanding of the 
molecular basis of CPT deficiency in man we purified 
CPT from human liver, raised polyclonal antibodies 
against his enzyme and determined partial amino acid 
sequences. 
2.1. Enzyme assays 
CPT was assayed in the forward reaction by the 5,5'-dithio- 
bis-2-nitrobenzoic a id (DTNB) method [6]. The mixture contained 
0.1 mM palmitoyl°CoA, 0.2 mM (DTNB), 0.1 M Tris-HCl (pH 8), 0.5 
mM EDTA, 0.1070 Tween-20. The reaction was started by adding 1 
mM L-carnitine. One unit of enzyme activity corresponds to one/~mol 
of palmitoyl-carnitine/min/mg. For the determination of pH op- 
timum, the activity was assayed using 0.1 M potassium 
phosphate/Tris-glycine buffer, adjusted to the desired pH. 
CPT activity was also assayed by following the formation of 
palmitoyl-CoA from CoASH and palmitoyl-carnitine (backward 
reaction) at 23 nm at 25°C [7]. The reaction mixture contained 91 mM 
Tris-HC1 (pH 7.6), 0.19 mM CoASH and 5.5 mM palmitoyl- 
carnitine. In order to determine if human CPT is inhibited by 
malonyl-CoA the activity was assayed by the DTNB method in the 
presence of 0.1 mM octanoyl-CoA or palmitoyl-CoA and 0-0.1 mM 
malonyl-CoA. The reaction was started by adding the enzyme. Since 
rat CPT inhibition by malonyl-CoA is abolished by Tween-20 [8], 
such detergent was not present in the reaction buffer. The assay 
described by Solbert [9] was also used to check malonyl-CoA inhibi- 
tion. The mixture contained 0.45 ml of 0.11 M Tris-HCl (pH 7.8), 5.6 
mM GSH and 0.13 mM palmitoyl-CoA; the concentration of 
malonyl-CoA ranged from 0-0.1 mM. The reaction was started by 
100/zl of 6 mM L-[aH]carnitine, carried out at 30°C for 5 min and 
stopped with 1 ml isobutanol. One ml of saturated ammonium 
sulphate was added and the solution'stirred. After centrifugation, 
700-800 #1 of supernatant were collected, the pellet washed with 1 ml 
of saturated ammonium sulphate and centrifuged [9]. The amount of 
radioactivity was determined in 500/~1 of the combined supernatants. 
Protein concentrations were estimated using bicinchoninic acid 
[10], according to the manufacturers' instructions (Pierce). 
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2.2. Purification and properties of human CPT 
Normal human liver obtained 20-24 h after death was stored at 
- 80°C. In a typical experiment 91 g of liver were homogenized in 350 
ml of 20 mM Tris-HC1 (pH 9.5), 5 mM EDTA, 0.5 mM 
phenylmethane sulphonyl fluoride, 0.5 mM phenantroline (buffer A). 
The suspension was centrifuged at 40 000 × g for 30 rain. The pellet 
obtained was resuspended by sonication in buffer A plus 0.5% 
Tween-20, and centrifuged at 40 000 x g for 30 min. The supernatant 
was diluted three-fold with deionized water and applied to a DEAE- 
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Table 1 
Purification steps of CPT from human liver 
November 1990 
Step Activity Proteins Specific activity Purification Yield 
~mol) (mg) ~mol/mg) (-fold) (070) 
1. Pellet-extract 49.0 6473.0 0.007 - - 
2. DEAE Seph. CL-6B 22.5 1720.0 0.013 1.9 45.9 
3. CM-Sepharose 21.6 1200.0 0.018 2.6 44.1 
4. Hydroxyapatite 10.9 256.0 0.043 6.1 22.2 
5. Matrex Gel Blue A 7.2 13.8 0.522 74.6 14.7 
6. Agarose Hexane CoA 4.1 1.0 4.100 585.7 8.4 
Sepharose CL-6B column equilibrated with 7 mM Tris-HCl (pH 9.5), 
1 mM EDTA, 0.1 o70 Tween-20 (buffer B). The sample was eluted with 
a 0-0.4 M NaCI linear gradient in buffer B. Fractions containing CPT 
were combined and dialized against 10 mM potassium phosphate (pH 
6.5), 1 mM EDTA, 0.1070 Tween-20 (buffer C). The sample was ap- 
plied to CM-Sepharose column equilibrated with buffer C. The void 
fraction was brought o pH 7 with a few drops of 5 N KOH and ap- 
plied to a hydroxyapatite column equilibrated with 10 mM potassium 
phosphate (pH 7), 0.1070 Tween-20 (buffer D). A 0.01-0.4 M linear 
gradient of potassium phosphate (pH 7), 0.1070 Tween-20 was used for 
the elution. Eluted CPT was dialized against 10 mM potassium 
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Fig. 1. Markers of molecular mass and two aliquots of purified CPT 
( - 5 p.g each) were loaded onto a 1007o SDS-PAGE slab gel and blot- 
ted onto nitrocellulose. One part of the filter was stained with 
Coomassie blue (lane a, Mr markers; lane b, purified CPT). The other 
was matched with 100-fold diluted anti-CPT antiserum, and the im- 
munoblot was performed as described in [17] (lane c). 
phosphate (pH 8), 0.5 mM EDTA, 0.1070 Tween-20 (buffer E). The 
sample was applied to a Matrex Gel Blue A column equilibrated with 
buffer E. A 0-0.8 M linear gradient of NaCI in buffer E was used for 
the elution. Fractions containing CPT were pooled, dialized against 5
mM potassium phosphate, 0.5 mM EDTA, 0.1070 Tween-20 (buffer F) 
and applied to an Agarose Hexane-CoA column equilibrted with buf- 
fer F. The sample was eluted with a 0.005-0.150 M linear gradient of 
potassium phosphate pH 7, 0.1070 Tween-20. The native molecular 
mass of CPT was determined by gel filtration using a Sephacryl S-300 
column calibrated with gel filtration standards (Pharmacia). To deter- 
mine the subunit molecular mass, CPT purified from human liver was 
electrophoresed ona 10°70 SDS-polyacrylamide g l [11]. The gel was 
stained with 0.25070 (w/v) Coomassie brilliant blue and destained with 
10070 (v/v) acetic acid/40% (v/v) methanol solution. The band ob- 
tained was then compared with standard proteins of high molecular 
mass (BioRad). The isoelectric point was determined by Ampholine 
PAG-plates pH 3.5-9.5 (Pharmacia-LKB) [12]. 
2.3. Preparation of anti-CPT antisera 
One ml of a mixture containing 0.5 mg of purified CPT and Freund 
adjuvant were injected in the back of white New-Zealand rabbit. The 
animal was boosted twice with 0.25 mg of CPT solution and 
semicomplete adjuvant and bled 10 days after the last booster. 
2.4. Isolation and sequencing of tryptic peptides 
Tryptic digestion and HPLC analysis of purified human CPT (132 
#g) was performed as described [ 13]. For the determination f the N- 
terminal sequence we used CPT blotted onto Immobilon membranes 
(Amicon) [141. 
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Fig. 2. Plot of the log of Mr markers (vertical axis) and elution volume 
from Sephacryl S-300 column (horizontal axis). The elution volume 
of human CPT (98 ml) is indicated by the arrow. 
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Table II 
Kinetic profiles of CPT from human liver 
November 1990 
Substrate Km QzM) Vmax 
Acetyl-CoA - 0.5 
Hexanoyl-CoA 151.5 2.1 
Octanoyl-CoA 22.9 3.4 
Decanoyl-CoA 16.7 6.3 
Lauroyl-CoA 11.0 7.9 
Myristoyl-CoA 30.8 5.5 
Palmitoyl-CoA 12.2 4.1 
Stearoyl-CoA 18.0 0.7 
L-carnitine with 0.1 mM octanoyl-CoA 
L-carnitine with 0.1 mM lauroyl-CoA 
L-carnitine with 0.1 mM myristoyl-CoA 
L-carnitine with 0.1 mM palmitoyl-CoA 
L-carnitine with 0.1 mM stearoyl-CoA 
Palmotoyl-L (-)-carnitine 
Octanoyl-L (-)-carnitine 
5014 
400 
593 
386 
348 
123 
1139 
3. RESULTS AND DISCUSSION 
CPT has been purified to homogeneity from beef 
heart and rat liver mitochondria [8,15], but never from 
human tissues. We purified human CPT by enriching 
its activity almost 600 times over that of the liver 
membrane-fraction extracted with Tween-20 (Table I). 
The final purified preparation showed a 66 kDa 
band, as determined by SDS-PAGe (Fig. 1, lane 2), 
while rat liver CPT seems to be 1-2 kDa larger than its 
human counterpart [16]. Gel filtration experiments in- 
dicated that native human CPT has a molecular mass of 
274 kDa, suggesting that this enzyme is a homotetramer 
(Fig. 2). These observations are in agreement with those 
obtained from CPT purified from rat liver mitochon- 
dria [8]. 
The pH optimum for CPT resulted to be 8.5. The 
isoelectric point was 6.4. The comparison f the kinetic 
parameters shown in Table II with those of human car- 
nitine acetyl-transferase [17] and rat carnitine octanoyl- 
transferase [8], clearly indicate that the protein we 
purified is indeed CPT. 
We checked whether purified human liver CPT was 
inhibited by malonyl-CoA. No inhibition was observed, 
in agreement with the observations by Woeltje, K.F. et 
al. [16] that rat liver CPT extracted by Tween-20 is not 
inhibited by malonyl-CoA. The lack of inhibition was 
observed not only with palmitoyl-Coa but also with 
octanoyl-CoA as a substrate, a result which is different 
from that obtained with CPT [18]. Whether this lack of 
inhibition is due to the separation of the purified en- 
zyme from its membrane environment or to the ex- 
istence of another, malonyl-CoA inhibitable CPT 
isoenzyme, is still controversial. 
We raised polyclonal antibodies against human CPT. 
The antiserum obtained is effective for both im- 
munoblotting (Fig. 1, lane c) and immunoprecipitation 
of human CPT and is therefore suitable for im- 
munologicai studies of patients affected by CPT defi- 
ciency. Seven peptides out of 163 obtained from tryptic 
digestion of human CPT were sequenced, yielding 148 
amino acidic residues. Furthermore, human CPT blot- 
ted onto Immobilon was also used for the determina- 
tion of the N-terminal sequence, yielding 14 more 
residues. As a whole, these sequences account for more 
than 25°7o f the sequence of mature CPT. 
Their comparison with the amino acid sequence of 
rat liver CPT [18] shows a high degree of homology, 
ranging from 78.6°7o to 96.2% (Table III). All the pep- 
tides sequenced were therefore derived from CPT, 
Table III 
Amino acid sequences of CPT from human liver* 
Peptide 93: DIWAELR (85.7°70) 
Peptide 115: HTSYISGPWFDMYLSAR (94.1070) 
Peptide 124a: GNFYIFDVLDQDGNIVSPSEIQAFIL (84070) 
Peptide 124b: DSVVLNFNPFMAFXP (92.9070) 
Peptide 130a: GIILPELYLDPAYGQINHNVLSTSTLSSPAVNLGGFAPVVSDGF (81.8070) 
Peptide 130b: QKLSPDAVAQLXFQMXXL (86.7070) 
Peptide 132: FVPSSLSWYGAYLVNAYPLDMSQYFR (96.207o) 
N-terminal: SAGSGPGQYXQXSIVP (78.6°70) 
*The homology with the corresponding sequence in rat liver CPT [14] is shown in parentheses. 
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strongly suggesting that the purified enzyme was essen- 
tially free of contaminants. 
The definition of human CPT properties and the 
availability of anti-human CPT antibodies should allow 
a deeper understanding of the structural basis of clinical 
heterogeneity n CPT deficiency. Furthermore, the par- 
tial amino acid sequences obtained from purified CPT 
are an indispensable tool for the identification of the 
cDNA encoding such an enzyme. 
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